Rac1 Modulates Endothelial Function and Platelet Aggregation in Diabetes Mellitus

Area of Science:

• Biochemistry
• Cardiovascular Biology
• Diabetes Research

Background:

• Diabetes mellitus is linked to vascular complications and abnormal platelet function.
• The Rho-related GTPase protein, Rac1, influences endothelial and platelet function.
• Rac1 is a potential therapeutic target for managing diabetes complications.

Purpose of the Study:

• To investigate the effects of pharmacological Rac1 inhibition on vascular and platelet function in diabetes.
• To evaluate Rac1 as a therapeutic target for hyperglycemia-induced complications.

Main Methods:

• In vitro and ex vivo studies using diabetic mice and human subjects.
• Administration of NSC23766, a Rac1 inhibitor.
• Assessment of endothelial function, nitric oxide (NO) levels, oxidative stress, and platelet aggregation.

Main Results:

• NSC23766 protected against hyperglycemia-induced endothelial dysfunction and restored NO levels.
• Rac1 inhibition reduced oxidative stress mediated by nicotinamide adenine dinucleotide phosphate oxidase.
• Human platelets in hyperglycemia showed Rac1 hyperactivation and impaired NO release, partially restored by NSC23766.
• NSC23766 demonstrated antiplatelet effects, reducing aggregation in diabetic patients.

Conclusions:

• Pharmacological inhibition of Rac1 is a promising therapeutic strategy for diabetes.
• This approach can mitigate endothelial dysfunction and reduce platelet hyperaggregation in diabetes mellitus.